# First in Human Dose Escalation Study of Vactosertib (TEW-7197) in Subjects With Advanced Stage Solid Tumors

> **NCT02160106** · PHASE1 · COMPLETED · sponsor: **MedPacto, Inc.** · enrollment: 35 (actual)

## Conditions studied

- Advanced Stage Solid Tumors

## Interventions

- **DRUG:** TEW-7197

## Key facts

- **NCT ID:** NCT02160106
- **Lead sponsor:** MedPacto, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07-29
- **Primary completion:** 2018-07-31
- **Final completion:** 2018-08-28
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2019-05-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02160106

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02160106, "First in Human Dose Escalation Study of Vactosertib (TEW-7197) in Subjects With Advanced Stage Solid Tumors". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02160106. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*